Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,428,502
  • Shares Outstanding, K 49,406
  • Annual Sales, $ 21,340 K
  • Annual Income, $ -91,410 K
  • 36-Month Beta 1.75
  • Price/Sales 84.84
  • Price/Cash Flow N/A
  • Price/Book 4.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.76
  • Number of Estimates 3
  • High Estimate -0.64
  • Low Estimate -0.87
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -111.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.25 +18.98%
on 01/23/19
50.40 -0.26%
on 02/20/19
+6.23 (+14.15%)
since 01/22/19
3-Month
35.04 +43.46%
on 12/24/18
50.40 -0.26%
on 02/20/19
+10.56 (+26.59%)
since 11/21/18
52-Week
30.00 +67.57%
on 03/19/18
50.40 -0.26%
on 02/20/19
+9.42 (+23.06%)
since 02/22/18

Most Recent Stories

More News
Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global...

ARNA : 50.27 (+2.28%)
Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019, after the close of the U.S. financial markets. The Company...

ARNA : 50.27 (+2.28%)
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full...

ARNA : 50.27 (+2.28%)
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational...

ARNA : 50.27 (+2.28%)
UTHR : 118.30 (+1.09%)
United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement,...

ARNA : 50.27 (+2.28%)
UTHR : 118.30 (+1.09%)
Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from the open-label extension (OLE) of the Phase 2 OASIS trial of its investigational drug candidate etrasimod, a next-generation,...

ARNA : 50.27 (+2.28%)
Interesting ARNA Put And Call Options For February 8th

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the February 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options...

ARNA : 50.27 (+2.28%)
Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 37th Annual J.P. Morgan Healthcare...

JPM : 105.00 (-0.45%)
ARNA : 50.27 (+2.28%)
Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience...

ARNA : 50.27 (+2.28%)
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings

NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working...

ARNA : 50.27 (+2.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ARNA with:

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

2nd Resistance Point 51.01
1st Resistance Point 50.64
Last Price 50.27
1st Support Level 49.53
2nd Support Level 48.79

See More

52-Week High 50.40
Last Price 50.27
Fibonacci 61.8% 42.61
Fibonacci 50% 40.20
Fibonacci 38.2% 37.79
52-Week Low 30.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar